Cascade Prodrug Appointed Kenneth Mandell to Board
The Eugene-based biotech firm added the CEO and inventor to its board as it advances its lead drug candidate.
Updated on Sept. 29, 2026 in People
Cascade Prodrug Inc. has appointed Dr. Kenneth Mandell to its Board of Directors. The company seeks his expertise in clinical development to assist in advancing its lead candidate, CPD100.
Why it matters
The company is leveraging Mandell's background in biotechnology entrepreneurship and clinical science to guide CPD100 toward clinical trials. This move aims to accelerate the drug's progress for treating wet age-related macular degeneration.
Dr. Kenneth Mandell holds an M.D. and a Ph.D. and is an inventor on more than 15 issued U.S. patents. He also maintains an adjunct appointment at the Massachusetts Institute of Technology.
The players
Kenneth Mandell
He is the Founder and CEO of LayerBio, Inc. and serves on the boards of Proteris Biotech and the Usher III Initiative.
Cascade Prodrug Inc.
Headquartered in Eugene, the company is a biotechnology firm focused on advancing its lead candidate CPD100 for wet age-related macular degeneration.
The details
Mandell, who founded and leads LayerBio, Inc., brings extensive experience in drug invention, having co-invented the nasal spray TYRVAYA and reproxalap eye drops. Cascade Prodrug is currently pushing CPD100 through preclinical development and toward IND-enabling studies.
Timeline
September 29, 2026: Cascade Prodrug Inc. announced the board appointment.
Market Landscape
This appointment highlights the ongoing integration of academic research from the Massachusetts Institute of Technology into private-sector drug development pipelines. The firm is actively positioning itself to compete in the ophthalmic space by securing leadership with a proven record of successful drug commercialization.
For investors and industry followers, this leadership change signals a heightened focus on the clinical progression of the company's macular degeneration treatment. Patients and providers should look for further updates regarding the firm's transition from preclinical development to human trials.
The takeaway
Mandell's appointment underscores the critical need for biotech firms to pair technical patent expertise with clinical development strategy to reach market milestones. Bringing in leaders with proven success in drug commercialization is a strategic necessity for early-stage companies advancing novel therapies.
Further reading
For more information on organizational shifts in the region, visit the Eugene People section.
More information
For more information, visit the company corporate website.
